Anixa Biosciences (ANIX) Jumps Almost 20% Despite Overall Market Losses

Despite a rough day in the market overall, Anixa Biosciences (ANIX) managed to leap almost 20% for the day. The Company announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology Meeting, which is being held in early June.

The presentation, titled “Phase 1 Trial of an alpha-Lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC),” will be presented by the Dr. George Thomas Budd, the study’s principal investigator.

Anixa is a biotech company focused on the treatment and prevention of cancer and infectious diseases, and is housed in the PRISM MedDiagnostics index, which was down 1.9% for the day. Anixa was the best performer in the index for the day.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa’s portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants like Delta and Omicron. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on TwitterLinkedIn and Facebook.


Share This Article


About the Author

Anixa Biosciences (ANIX) Jumps Almost 20% Despite Overall Market Losses

Editor Prism MarketView